Developmental Funds

发展基金

• 批准号: 10177895
• 负责人: ROBERT S. MANNEL
• 金额: $ 26.55万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10177895
• 关键词: Address; Award; Biometry; Cancer Center; Cancer Center Support Grant; Clinical Cancer Center; Clinical Investigator; Clinical Sciences; Cytometry; Development; Direct Costs; Emerging Technologies; Ensure; Evaluation; Extramural Activities; Foundations; Funding; Funding Mechanisms; Goals; Grant; Growth; Health Technology; Investments; Leadership; Medical Research; Mission; Molecular Biology; Monitor; Oklahoma; Pathology; Peer Review; Pilot Projects; Play; Publications; Research; Research Design; Research Infrastructure; Research Personnel; Research Priority; Resource Allocation; Resource Sharing; Rest; Role; Science; Scientific Advances and Accomplishments; Secure; Services; Source; Strategic Planning; Structure; Therapeutic; Tissues; Underserved Population; anticancer research; base; cancer health disparity; cancer research center director; drug discovery; effectiveness evaluation; effectiveness outcome; innovation; interdisciplinary collaboration; mHealth; new technology; patient derived xenograft model; personalized cancer therapy; pre-clinical; programs; recruit; translational cancer research

DEVELOPMENTAL FUNDS – ABSTRACT Developmental funds from institutional, state and philanthropic sources have been critically important in the growth of the Stephenson Cancer Center (SCC) since its inception. Over the past five years, the SCC has utilized developmental funds to advance the following key research priorities defined in the SCC's 2012-2016 Strategic Plan: 1) stimulating transdisciplinary and collaborative science within the SCC's programs; 2) advancing scientific findings through the development pipeline into NCTN and other trials; 3) conducting research to address cancer health disparities among underserved populations in Oklahoma; 4) supporting early-stage clinical investigators who are actively involved in the SCC's clinical science effort; and 5) investing in new emerging technologies and technical services to support programmatically aligned cancer research at the SCC. All decisions concerning the allocation of developmental funds ultimately rest with the SCC Director, who meets with his senior leadership team biweekly to discuss new research opportunities and potential allocation of resources for intramural grants, recruitment, and investments in new technologies. Intramural pilot grants supported by developmental funds have played a major role in advancing the SCC's mission and goals, providing the means for the SCC to pursue new research opportunities and achieve broad strategic objectives as well as providing the means for program leaders to achieve targeted scientific objectives. The SCC has strategically utilized developmental funds through competitively awarded pilot project and directed-funding mechanisms, including a major team-based award mechanism to support multi-PI projects with high potential of leading to PPG submissions, to stimulate research and enhance transdisciplinary collaborations. Over the past five years (CY2012-2016), the SCC has awarded 59 pilot grants, with a total award amount of $3,910,492. To date, these grants have resulted in 106 peer-reviewed publications and $28,227,492 (total, direct cost) in extramural sponsored research funding (as of 4/15/17). Developmental funds have allowed the SCC to establish and enhance research infrastructure, including the Biostatistics and Research Design, Tissue Pathology, Molecular Biology and Cytometry Research, and Mobile Health Technology Shared Resources. For the upcoming five-year period, the SCC is requesting developmental funds to support the growth of a Patient-Derived Xenograft and Preclinical Therapeutics (PDX- PCT) Core housed at the Oklahoma Medical Research Foundation (OMRF), the SCC's proposed consortium partner. Established in 2015, this Core provides SCC investigators and other campus investigators with high- quality services for basic and translational cancer research, drug discovery and personalized cancer therapy. The goal is to develop the PDX-PCT Core into a formal shared resource within a five-year timeframe.

发展基金--摘要 来自机构、国家和慈善来源的发展资金在 斯蒂芬森癌症中心(SCC)自成立以来的增长。在过去的五年中，SCC 利用发展资金推进SCC 2012-2016年确定的下列关键研究优先事项 战略计划：1)在SCC的项目中促进跨学科和协作科学；2) 通过开发管道将科学发现推进NCTN和其他试验；3)进行 解决俄克拉荷马州未得到充分服务的人群中癌症健康差距的研究；4)支持 积极参与SCC临床科学工作的早期临床研究人员；以及5)投资 在新的新兴技术和技术服务方面，支持按计划进行的癌症研究 SCC。关于发展资金分配的所有决定最终由SCC主任决定， 世卫组织每两周与他的高级领导团队会面，讨论新的研究机会和潜力 分配资源，用于校内赠款、招聘和新技术投资。 由发展基金支持的校内试点赠款在推动SCC的 使命和目标，为SCC寻求新的研究机会和实现广泛的目标提供手段 战略目标，并为项目负责人提供手段，以实现有针对性的科学 目标。SCC通过竞争获奖的试点项目，战略性地利用发展资金 和定向资助机制，包括以团队为基础的主要奖励机制，以支持多PI 有很高潜力导致PPG提交的项目，以刺激研究和促进跨学科 合作。在过去五年(2012-2016财年)，SCC共授予59项试点助学金，总计 赔偿额3910,492美元。到目前为止，这些赠款已经产生了106份同行评议的出版物和 28227,492美元(总额，直接费用)，为外部资助的研究资金(截至2017年4月15日)。 发展基金使SCC能够建立和加强研究基础设施，包括 生物统计学和研究设计、组织病理学、分子生物学和细胞测量研究，以及移动 健康科技共享资源。对于即将到来的五年期间，SCC要求 支持患者来源的异种移植和临床前治疗(PDX- PCT)位于俄克拉荷马医学研究基金会(OMRF)的核心，该基金会是SCC提议的财团 搭档。该核心成立于2015年，为SCC调查人员和其他校园调查人员提供高质量的 为基础和转化型癌症研究、药物发现和个性化癌症治疗提供优质服务。 目标是在五年内将PDX-PCT核心发展成为正式的共享资源。